Actively Recruiting
DAratumumab and REvlimid REfractory MM
Led by Fondazione IRCCS Policlinico San Matteo di Pavia · Updated on 2024-08-07
100
Participants Needed
1
Research Sites
261 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Retrospective and prospective multicenter observational study on patients with relapsed and refractory multiple myeloma after anti-CD38 MoAb therapy and IMIDS treated with onlabel regimens.
CONDITIONS
Official Title
DAratumumab and REvlimid REfractory MM
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Patients with relapsed and refractory multiple myeloma after therapy with anti-CD38 monoclonal antibodies plus immunomodulatory drugs started on therapy with the PVD scheme (Phase I)
- Patients aged 18 years or older
- Patients able to understand and voluntarily sign an informed consent and willing to consent to the review of clinical data
- Patients with relapsed and refractory multiple myeloma after first-line therapy with anti-CD38 monoclonal antibodies plus immunomodulatory drugs started on therapy with on-label schemes (Phase II)
You will not qualify if you...
- Patients not willing to consent to the review of clinical data
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Irccs San Matteo Pavia
Pavia, PV, Italy, 27100
Actively Recruiting
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
0
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here